

Proceeding Paper

Revitalizing Antibiotics: Strategies to Combat Resistance and Restore Effectiveness [†]

Devendra Kumar Mishra *, Ila Dixit, Sumit Chaudhari, Sandeep Yadav, Lavkush Tiwari, Khalid Abdul Waheed and Savita Upadhyay

Ambekeshwar Institute of Pharmaceutical Sciences, Lucknow 226201, Uttar Pradesh, India; ilashukla27@gmail.com (I.D.); dynamicsumitchaudhari@gmail.com (S.C.); sy991961@gmail.com (S.Y.); lavkusht81@gmail.com (L.T.); ksiddiqui900@gmail.com (K.A.W.); upadhyaysavita.agi1018@gmail.com (S.U.)

* Correspondence: devendra4747@gmail.com; Tel.: +91-9453474719

[†] Presented at the 3rd International Electronic Conference on Antibiotics (ECA 2023), 1–15 December 2023;

Available online: <https://eca2023.sciforum.net/>.

Abstract: The rising issue of antibiotic resistance has emerged as a serious global health problem, compromising our capacity to successfully tackle bacterial diseases. Antibiotic abuse and misuse have hastened the development of resistance, leaving many once-effective medications useless. This research investigates ways for reversing antibiotic resistance, with a special emphasis on rejuvenating older drugs. Several main techniques are being investigated in the attempt to “Make Old Antibiotics Great Again.” First, we investigate the mechanisms behind antibiotic resistance, offering information on the evolutionary processes that drive bacterial adaptability. Following that, we will look at the possibilities of antibiotic combination treatment, a strategy that can improve the efficacy of older antibiotics by utilising synergistic drug interactions. Furthermore, we investigate the potential of antibiotic stewardship programmes, stressing the ethical use of antibiotics to lessen selection pressure for resistant bacteria. Rapid molecular testing, for example, is highlighted as a vital tool for accurate antibiotic selection, improving treatment regimens, and limiting resistance development. The importance of research and development activities in the quest to discover new antibiotics is underlined, as it provides a long-term solution to the resistance challenge. Furthermore, we discuss the importance of policy interventions and global cooperation in creating the landscape of antibiotic resistance, eventually recommending a united response to this critical issue. In summary, this study underlines the need to reverse antibiotic resistance, emphasises the potential of older antibiotics when used wisely, and recommends a holistic strategy incorporating scientific, medical, and policy strategies to address this emerging danger to public health.

Keywords: antibiotic resistance; antibiotic abuse; synergistic drug interactions; antibiotic stewardship programs



Citation: Mishra, D.K.; Dixit, I.; Chaudhari, S.; Yadav, S.; Tiwari, L.; Waheed, K.A.; Upadhyay, S. Revitalizing Antibiotics: Strategies to Combat Resistance and Restore Effectiveness. *Med. Sci. Forum* **2024**, *24*, 4. <https://doi.org/10.3390/ECA2023-16391>

Academic Editor: Marc Maresca

Published: 30 November 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Antibiotics were one of the most important medical advances of the 20th century. They effectively treat bacterial infections and have saved many lives [1]. But antibiotics are being used too much and in the wrong way, and bacteria are becoming resistant to antibiotics very quickly. This has led to the rise of antibiotic-resistant bacteria, which are very dangerous to public health [2]. In this review paper, the current state of antibiotic resistance is looked at, along with the methods being used to fight it and make these life-saving drugs work again.

2. Antibiotic Resistance Mechanisms

Antibiotic resistance mechanisms are the different ways that bacteria get around antibiotics' effects. Genetic mutations, horizontal gene transfer, biofilm formation, efflux pumps, and reduced permeability are some of the groups these mechanisms can be put into. Here's a quick look at each of these mechanisms.

2.1. Genetic Mutations

The genome of bacteria can have genetic mutations, which change certain genes or DNA sequences. These changes can impact the area that antibiotics work on, the expression of resistance genes, or other parts of the bacterial body. Changes in the genes that make ribosomal proteins can make antibiotics like tetracycline less likely to bind to the bacterial ribosome. This makes the bacteria resistant to these drugs [1].

2.2. Horizontal Gene Transfer

Bacteria can give genetic material to other bacteria, including genes that make them resistant to antibiotics. This can happen through conjugation, transformation, and transduction. This makes it easy for resistance genes to quickly spread through bacterial populations. If one bacterium has a plasmid with a resistance gene on it, it can conjugate with another bacterium and give the recipient plasmid antibiotic resistance [3].

2.3. Biofilm Formation

Biofilms are groups of bacteria that are embedded in a matrix that the bacteria make themselves. Antibiotics and immune system responses cannot hurt biofilms, which makes bacteria inside them more resistant. Antibiotics may not work well on bacterial biofilms that form on medical devices like catheters because the biofilm structure makes it hard for drugs to get through [4].

2.4. Efflux Pumps

Efflux pumps are special proteins that move antibiotics out of bacterial cells. This lowers the amount of drug inside the cells, which makes the antibiotics less effective. Multidrug efflux pumps, like the AcrAB-TolC system in *Escherichia coli*, can push out a lot of different antibiotics. This makes the bacteria resistant to many drugs [5].

2.5. Reduced Permeability

While antibiotics try to get into some bacteria cells, they are stopped by defences that are already there. To keep drugs out, the structure of the cell membrane or wall may need to be changed. Antibiotics have a hard time getting inside *Mycobacterium tuberculosis* because of the way its cell wall is built. This means that it is naturally not sensitive to many drugs [6].

3. The Global Impact of Antibiotic Resistance

Antibiotic resistance affects people all over the world in ways that go beyond health care. It has many effects on the health of people and animals, the environment, and the economy. Here is a summary of how antibiotic resistance affects these areas around the world

3.1. Human Health

- **Treatment failures:** Infections that are resistant to antibiotics can be hard to treat, which can make people sick longer, kill more people, and require antibiotics that are more expensive or harmful.
- **Increased healthcare costs:** It can be hard on healthcare budgets to treat infections that are resistant because they often require longer hospital stays, more diagnostic tests, and more expensive drugs.
- **Public health threat:** It is dangerous for the public's health when resistant bacteria get around in communities and healthcare settings. It gets harder to take care of common infections like urinary tract infections and surgical site infections [2].

3.2. Animal Health

- **Agricultural use:** A lot of antibiotics are used in farming to help animals grow and stay healthy when they are crowded together. This makes it easier for bacteria that are resistant to antibiotics to grow in animals.
- **Food safety concerns:** Resistance bacteria can be passed from one food source to another, which could be bad for people's health. People can get resistant pathogens from meat, milk, and other animal products that have been tainted [7].

3.3. Environmental Impact

- **Antibiotic residues:** Healthcare facilities and farms can pollute water and soil by dumping antibiotics and bacteria that are resistant to antibiotics into wastewater that then gets into the environment.
- **Ecological consequences:** Genes that make bacteria resistant to antibiotics can be passed on to bacteria in the environment. This could change natural microbial communities and the way ecosystems work [8].

3.4. Economic Consequences

- **Increased healthcare expenditure:** As the number of infections that are resistant to antibiotics rises, healthcare costs rise, including higher costs for hospital stays and medicines;
- **Loss of productivity:** People who are sick, including people who work, may be less productive because they take longer to get better or become disabled because of infections that are resistant to treatment;
- **Impact on agriculture:** Animals that are resistant to antibiotics can hurt agricultural production, which could cost the farming industry money [9].

4. Strategies to Combat Antibiotic Resistance

One of the most important things for global health is to fight antibiotic resistance. Several approaches are being used to deal with this problem, ranging from using antibiotics in a smart way to creating new treatments. To fight antibiotic resistance, here are some important things you can do.

4.1. Stewardship Programs

Antibiotic stewardship programmes encourage healthcare workers to use antibiotics smartly. They want to improve how antibiotics are prescribed, make sure the right doses and lengths of time are used, and cut down on use that is not necessary. Stewardship programmes help lower the selection pressure for antibiotic resistance, which slows the growth of antibiotic-resistant bacteria and keeps antibiotics that are already in use working well [10].

4.2. Antibiotic Development

To stop antibiotic resistance from spreading, we need to make new antibiotics with new ways of working. This includes finding new antimicrobials, making them, and testing them in people. New antibiotics can treat infections caused by pathogens that are resistant to antibiotics. This is a very important tool in the fight against antibiotic resistance [11].

4.3. Combination Therapy

Combination therapy is a way to treat infections that uses two or more antibiotics that work in different ways. By going after bacteria in more than one way, this method can help stop the development of resistance. Combining antibiotics can make treatment more effective and slow the development of resistance, especially for infections that are severe or hard to treat [12].

4.4. Phage Therapy

As an alternative to antibiotics, phage therapy uses bacteriophages, which are viruses that infect and kill certain bacteria. Phages can be directed at the pathogen that is infecting the person. Phage therapy is a very targeted and possibly effective way to treat bacterial infections with little chance of making the bacteria more resistant [13].

4.5. Immunotherapies

Immunotherapies try to make the body's defences stronger against bacterial infections. Some of these treatments are vaccines, monoclonal antibodies, and others that work on the immune system. By making the body's natural defences stronger, immunotherapies can help stop infections, cut down on the need for antibiotics, and improve outcomes [14].

4.6. Alternative Therapies

To fight bacterial infections, different alternative treatments are being looked into, such as natural compounds, probiotics, and antimicrobial peptides. These treatments might be used instead of or in addition to regular antibiotics. Looking into alternative therapies expands the range of treatments that can be used, which could lead to less dependence on antibiotics and less antibiotic resistance [11].

5. The Role of a One-Health Approach

A "One Health" approach sees how the health of people, animals, and the environment are all connected and stresses the need for people from all of these areas to work together to solve tough health problems like antibiotic resistance. A "One Health" approach is very important for fighting antibiotic resistance in the following ways.

5.1. Human-Animal-Environment Connection

People, animals, and the environment can all become resistant to antibiotics because they share ecosystems and bacteria and genes that are resistant to antibiotics can be passed from one place to another. It is very important to understand this link because bacteria that are resistant to antibiotics can move between these domains. When bacteria become resistant in animals, they can infect humans. The environment can help choose which bacteria become resistant and spread them [15].

5.2. Surveillance and Data Sharing

Surveillance systems track antibiotic resistance in humans, animals, and the environment. Data on antibiotic usage, disease resistance, and resistance genes are exchanged across industries. Human and veterinary healthcare, environmental authorities, and academics share data to discover resistance trends and causes. It allows coordinated antibiotic-resistance fighting at its source. A One Health strategy brings together stakeholders from diverse sectors to fight antibiotic resistance:

- In human health: It is recommended that healthcare professionals support antibiotic stewardship programmes, encourage infection control measures, and prescribe antibiotics in a way that does not cause resistance.
- In Animal Health: Veterinarians and people who raise animals for food encourage animals to use antibiotics responsibly, limit the use of antibiotics to help animals grow and take steps to stop the spread of bacteria that are resistant to antibiotics in animal populations.
- In the environment: Antibiotic residues and their effect on resistance are tracked and managed by environmental agencies. They also figure out how things in the environment, like pollution, affect driving resistance.
- Data Sharing and Research: Researchers and agencies that work on human health, animal health, and the environment can better understand how antibiotic resistance works when they work together. This includes looking into the genetic causes of resistance, following its spread, and figuring out where help is most needed [16].

6. The Importance of Public Awareness

In the fight against antibiotic resistance, getting people to know about it is very important. Getting healthcare professionals and the public to understand and care more about this issue can help people use antibiotics more wisely and prevent infections better. Here are some important things people should know about antibiotic resistance.

6.1. Healthcare Provider Education

Doctors, nurses, and pharmacists are some of the most important people in prescribing and giving antibiotics. They can stay up to date on the best practices, the newest treatment guidelines, and how important it is to use antibiotics wisely through education and awareness campaigns. When doctors are well-informed, they are more likely to prescribe the right antibiotics, which can lower the pressure for antibiotic resistance. In turn, this helps keep antibiotics working well for future generations [17].

6.2. Patient Education

To properly use antibiotics, patients should be taught about how to complete a full course of antibiotics and the effects of antibiotic resistance. Additionally, they should know that antibiotics do not work on viral infections like the flu or the common cold. Empowering patients to make smart decisions about their health care is possible through patient education. Antibiotics may not be needed as much if this happens, so they are not overused or misused [18].

6.3. Responsible Antibiotic Use

Antibiotics should only be used when they are medically necessary, should be taken exactly as prescribed, and should not be shared or saved. Not putting too much pressure on doctors to give antibiotics when they are not needed is also part of it. To stop antibiotic resistance, it is important to promote responsible antibiotic use. This keeps antibiotics working as well as possible to treat serious bacterial infections [17].

7. Conclusions

Resistance to antibiotics is a major global problem that needs coordinated action from many groups. It is very important to find new antibiotics, but it is also very important to focus on safe antibiotic use, surveillance, and a “One Health” approach that looks at how the health of people, animals, and the environment are all connected. The growth and spread of bacteria that are resistant to antibiotics is a major public health threat because it can cause treatments to fail and healthcare costs to rise. We can try to bring antibiotics back to life and lessen the threat of antibiotic resistance by using all of these methods together and performing a lot of research and development.

Author Contributions: D.K.M., I.D., S.C., S.Y., L.T., K.A.W. and S.U.: conceptualization, methodology, data collection, writing—original draft preparation; D.K.M., I.D., S.C., S.Y., L.T., K.A.W. and S.U.: writing—reviewing and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the article.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Piddock, L.J.V. Understanding the basis of antibiotic resistance: A platform for drug discovery. *Microbiology* **2014**, *160 Pt 11*, 2366–2373. [[CrossRef](#)] [[PubMed](#)]
2. Ventola, C.L. The antibiotic resistance crisis: Part 1: Causes and threats. *Pharm. Ther.* **2015**, *40*, 277–283.

3. Smillie, C.S.; Smith, M.B.; Friedman, J.; Cordero, O.X.; David, L.A.; Alm, E.J. Ecology drives a global network of gene exchange connecting the human microbiome. *Nature* **2011**, *480*, 241–244. [[CrossRef](#)] [[PubMed](#)]
4. Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial biofilms: A common cause of persistent infections. *Science* **1999**, *284*, 1318–1322. [[CrossRef](#)] [[PubMed](#)]
5. Poole, K. Efflux-mediated antimicrobial resistance. *J. Antimicrob. Chemother.* **2005**, *56*, 20–51. [[CrossRef](#)] [[PubMed](#)]
6. Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. *Microbiol. Mol. Biol. Rev. MMBR* **2003**, *67*, 593–656. [[CrossRef](#)] [[PubMed](#)]
7. Morley, P.S.; Apley, M.D.; Besser, T.E.; Burney, D.P.; Fedorka-Cray, P.J.; Papich, M.G.; Traub-Dargatz, J.L.; Scott Weese, J. Antimicrobial drug use in veterinary medicine. *J. Vet. Intern. Med.* **2005**, *19*, 617–629. [[CrossRef](#)] [[PubMed](#)]
8. Knapp, C.W.; McCluskey, S.M.; Singh, B.K.; Campbell, C.D.; Hudson, G.; Graham, D.W. Antibiotic Resistance Gene Abundances Correlate with Metal and Geochemical Conditions in Archived Scottish Soils. *PLoS ONE* **2011**, *6*, e27300. [[CrossRef](#)] [[PubMed](#)]
9. Poudel, A.N.; Zhu, S.; Cooper, N.; Little, P.; Tarrant, C.; Hickman, M.; Yao, G. The economic burden of antibiotic resistance: A systematic review and meta-analysis. *PLoS ONE* **2023**, *18*, e0285170. [[CrossRef](#)] [[PubMed](#)]
10. Mas-Morey, P.; Valle, M. A systematic review of inpatient antimicrobial stewardship programmes involving clinical pharmacists in small-to-medium-sized hospitals. *Eur. J. Hosp. Pharm. Sci. Pract.* **2018**, *25*, e69–e73. [[CrossRef](#)] [[PubMed](#)]
11. Penesyan, A.; Gillings, M.; Paulsen, I.T. Antibiotic Discovery: Combatting Bacterial Resistance in Cells and in Biofilm Communities. *Molecules* **2015**, *20*, 5286–5298. [[CrossRef](#)] [[PubMed](#)]
12. Boyd, N.; Nailor, M. Combination Antibiotic Therapy for Empiric and Definitive Treatment of Gram-Negative Infections: Insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy* **2011**, *31*, 1073–1084. [[CrossRef](#)] [[PubMed](#)]
13. Moye, Z.D.; Woolston, J.; Sulakvelidze, A. Bacteriophage Applications for Food Production and Processing. *Viruses* **2018**, *10*, 205. [[CrossRef](#)] [[PubMed](#)]
14. Ramamurthy, D.; Nundalall, T.; Cingo, S.; Mungra, N.; Karaan, M.; Naran, K.; Barth, S. Recent advances in immunotherapies against infectious diseases. *Immunother. Adv.* **2021**, *1*, ltaa007. [[CrossRef](#)]
15. Behraves, C.B. One Health: People, Animals, and the Environment. *Emerg. Infect. Dis.* **2016**, *22*, 766–767. [[CrossRef](#)]
16. Velazquez-Meza, M.E.; Galarde-López, M.; Carrillo-Quiróz, B.; Alpuche-Aranda, C.M. Antimicrobial resistance: One Health approach. *Vet. World* **2022**, *15*, 743–749. [[CrossRef](#)] [[PubMed](#)]
17. Mainous, A.G., 3rd; Lambourne, C.A.; Nietert, P.J. Impact of a clinical decision support system on antibiotic prescribing for acute respiratory infections in primary care: Quasi-experimental trial. *J. Am. Med. Inform. Assoc. JAMIA* **2013**, *20*, 317–324. [[CrossRef](#)] [[PubMed](#)]
18. Althagafi, N.S.; Othman, S.S. Knowledge, attitude, and practice of antibiotics use among primary healthcare physicians, Ministry of Health, Jeddah. *J. Fam. Med. Prim. Care* **2022**, *11*, 4382–4388. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.